2. Home
  3. Overview
  4. Erectile Dysfunction

Stem Cell Therapy for Erectile Dysfunction (ED)

Erectile dysfunction (ED) is defined as persistent difficulty achieving or maintaining an erection sufficient for satisfactory sexual activity. It affects approximately 50% of men between the ages of 40 and 70.

Approximately 80% of ED cases have an identifiable physical cause, while around 10% are primarily associated with psychological factors. Conventional treatments can help manage ED, but they do not always restore natural erectile function.

At ANOVA IRM in Offenbach, Germany, selected patients may be evaluated for an autologous stem cell-based treatment approach. The treatment concept primarily focuses on Mesenchymal Stem Cell Secretome / Exosome therapy, also known as MSEC therapy, and is considered alongside established treatment options.

This page provides an overview of ED causes, established treatment options, precision diagnostics and ANOVA's stem cell-based approach. Stem cell-based treatment for ED remains experimental and requires an individual medical review to determine whether it is appropriate.

Erectile Dysfunction Treatment Overview

Jump directly to the following topics:

Mesenchymal stem cell secretome and exosome signalling in stem cell therapy for erectile dysfunction

MSC secretome - exosome - therapy
ANOVA IRM - Germany

Stem Cell Therapy for Erectile Dysfunction at ANOVA IRM

Stem cell-based therapy may be considered alongside appropriate established ED treatment rather than as a replacement.

Conventional treatment options for ED include:

  • Improving penile blood flow with oral PDE5 inhibitors such as sildenafil or tadalafil
  • Addressing cardiovascular, metabolic, hormonal, medication-related or lifestyle contributors
  • Providing psychological or psychosexual support when relevant
  • Supporting erections through injectable or intraurethral medication, vacuum devices or a penile prosthesis

PDE5 inhibitors are often used as first-line treatment and help many patients. However, some cannot take or tolerate them, while others do not achieve the desired response. Other options vary in invasiveness and may not suit every patient.

Even with treatment, spontaneous erectile function may remain impaired when underlying vascular changes, cavernosal nerve injury, or tissue damage persist.

This has encouraged research into regenerative approaches that examine the biological environment involved in erectile function. At ANOVA IRM, selected patients may be assessed for autologous MSEC therapy alongside appropriate established care.

Can Stem Cell Therapy Help Erectile Dysfunction?

Stem cell-based therapy for ED is being investigated as a regenerative approach, particularly when vascular, nerve or erectile-tissue damage contributes to symptoms.

Why Physical ED Is Relevant to Regenerative Research

Physical, or organic, ED can develop when blood flow, nerve signalling or smooth-muscle relaxation within the penis is impaired. Difficulty restricting venous outflow may also prevent an erection from being maintained.

Cavernous nerve injury following radical prostatectomy and conditions such as diabetes can disrupt these processes. Over time, ongoing damage may contribute to endothelial dysfunction, smooth-muscle loss and fibrosis within the erectile tissue.

Researchers have therefore studied how stem cells and stem cell-derived products may influence:

  • Blood-vessel signalling and the function of endothelial cells
  • Cavernous nerve injury and nerve-support pathways
  • Smooth muscle cell survival and function
  • Inflammation, oxidative stress and metabolic injury
  • Fibrosis and other tissue-remodelling processes

Most evidence for these proposed mechanisms is preclinical, meaning it comes from laboratory and animal studies. Human research remains limited to small phase I and II trials that used different living-cell products, treatment methods and patient groups. Some studies reported improvements, but the findings have varied and current evidence remains insufficient to support a clinical recommendation.

Because these studies evaluated living-cell products rather than ANOVA's cell-free MSEC therapy, they provide scientific background for the broader regenerative rationale rather than direct evidence for MSEC. MSEC contains no living stem cells; its rationale concerns the biological signals released by mesenchymal stem cells.

Whether that rationale may be relevant to an individual patient depends partly on the physical processes contributing to their ED. Identifying those processes is therefore an important part of ANOVA's assessment.

ED Diagnostics at ANOVA IRM: Revealing the Cause and Severity

Because ED often has more than one contributing factor, a comprehensive diagnostic assessment may be needed before an appropriate treatment approach can be determined.

ANOVA conducts advanced imaging in cooperation with the Prof. Stehling Institute for Diagnostic Imaging, located in the same building, drawing on Dr. Michael K. Stehling's background in radiology and physics.

Depending on the individual case, ANOVA's diagnostic assessment may include:

  • An ED questionnaire assessing general health, sexual function and specific symptoms
  • A physical examination by a urologist or andrologist
  • Blood testing, which may include glucose or HbA1c, a lipid profile and relevant hormone values such as testosterone
  • Doppler or duplex ultrasound of the penis and penile arteries
  • SKAT-MRI, a penile MRI performed during a pharmacologically induced erection, to evaluate structural and vascular contributors in selected cases

The results help identify underlying conditions that may require established treatment and inform whether MSEC therapy may be medically appropriate.

Learn more about our diagnostic work-up.

Diagram of penile blood flow, the corpora cavernosa and natural erectile function in flaccid and erect states

The erectile system of the penis. “Cross-Sectional Anatomy of the Penis” by Philschatz. License: CC BY 4.0. ANOVA IRM - Germany

Pharmacocavernosography and MRI showing venous leakage in a patient with organic erectile dysfunction

Erectile dysfunction - diagnostics:
A 43-year-old patient: (a) pharmacocavernosography does not show venous leakage clearly. (b) MRI: significant venous leakage (mixed type) is visualized, including a caverno-balanic shunt. ANOVA IRM - Germany

ANOVA IRM Treatment Approach for Erectile Dysfunction

At ANOVA IRM, ED treatment is planned within a regulated German medical setting and begins with a review of the diagnostic findings, medical history and previous treatment response.

ANOVA uses autologous treatment concepts derived from the patient's own biological material. For ED, the current approach primarily focuses on cell-free Mesenchymal Stem Cell Secretome / Exosome therapy, also known as MSEC therapy. Depending on the diagnostic findings and physician assessment, Bone Marrow Concentrate (BMC) may be used as a standalone treatment or combined with MSEC.

What Therapeutic Outcomes Can Be Expected?

Treatment goals are individualized and monitored through clinical, functional and imaging-related measures.

Potential treatment goals or monitoring areas may include:

  • Ability to achieve and maintain an erection
  • Penile rigidity and spontaneous or morning erections
  • Response to PDE5 inhibitors or other established therapies
  • Validated erectile-function scores
  • Penile blood-flow findings, sexual satisfaction and quality of life

The relevance of each goal depends on the cause and extent of the patient's ED.

Potency Hypothesis of Stem Cell Therapies

Mesenchymal stem cells communicate with nearby cells through substances they release, a process commonly described as paracrine signalling. In ED research, this signalling is being studied in relation to endothelial function, cavernosal nerve support, smooth-muscle survival, inflammation and tissue remodelling.

The stem cell secretome contains exosomes and other extracellular vesicles, growth factors, cytokines, proteins and microRNAs. Earlier research involving living-cell therapies has also considered engraftment and cellular differentiation, but those mechanisms do not apply to a cell-free product.

ANOVA's MSEC rationale therefore focuses on whether factors released by mesenchymal stem cells may influence the tissue environment involved in physical ED.

MSEC / Mesenchymal Stem Cell Secretome / Exosome-Containing Therapy

Mesenchymal Stem Cell Secretome, or MSEC, is a cell-free, exosome-containing treatment derived from cultivated mesenchymal stem cells. It uses the substances released by the cells rather than transplanting the living cells themselves.

At ANOVA IRM, MSEC is produced from the patient's own adipose-derived mesenchymal stem cells. A limited amount of abdominal fat is collected through mini-liposuction under light sedation. The cells are then cultivated, and the substances they release are separated from the living MSCs and quality-controlled.

A practical advantage of MSEC is that it can be frozen and stored for later applications. One mini-liposuction generally provides 10 planned MSEC doses that can be administered over a longer treatment period within the stored shelf life of two years. This avoids repeating the tissue collection for every treatment visit.

The timing and method of applications depend on the individual treatment plan.

Learn more about ANOVA IRM’s Secretome / Exosome therapies.

Who May Be a Candidate for Erectile Dysfunction Stem Cell Therapy?

As an experimental treatment, MSEC therapy is not suitable for every patient with erectile dysfunction.

ANOVA considers MSEC therapy for selected patients whose ED has a suspected or confirmed physical component. Suitability is determined through an individual medical review.

Patients who may be considered include those with:

  • Persistent ED with a suspected or confirmed physical component
  • Vasculogenic or neurogenic ED
  • Diabetic erectile dysfunction or ED associated with another metabolic condition
  • Post-prostatectomy erectile dysfunction or ED following another pelvic treatment, where medically appropriate
  • ED following relevant penile or pelvic trauma
  • Persistent symptoms despite established treatment or inability to use suitable established options
  • Medical suitability for the collection and application procedures required by the proposed treatment plan
  • Ability to travel to Offenbach, Germany, for evaluation and treatment

ANOVA IRM does not treat patients when the following contraindications apply:

  • Active cancer within the last two years
  • Not being of legal age
  • Inability to breathe independently or ventilator dependence
  • Difficulty breathing while lying down
  • Dysphagia or extreme difficulty swallowing
  • Psychiatric disorder
  • Active infectious disease, including hepatitis A, B or C, HIV, syphilis or another active infection
Diagram of mesenchymal stem cells releasing exosomes, microvesicles, cytokines, proteins and microRNA

MSC secretome - exosome - therapy
ANOVA IRM - Germany

Therapy Workflow for Erectile Dysfunction

What to Expect From the Treatment Process

The treatment pathway depends on whether the individual plan includes MSEC, BMC alone or a combination of both. ANOVA confirms the applicable preparation and scheduling requirements before treatment.

Step 1: Remote Erectile Dysfunction Inquiry Review

For international patients, the process normally begins remotely. After the patient submits ANOVA IRM's contact form, the patient care team explains the treatment concept and the information required for review.

A video consultation with Dr. Michael K. Stehling may then be arranged. ANOVA reviews the patient's ED history, current care and available diagnostic findings to determine whether an in-person assessment is appropriate.

Step 2: Pre-Treatment Eligibility Testing and Day-One Confirmation

Once initial suitability appears possible, ANOVA IRM generally recommends preliminary bloodwork in the patient's home country before travel. This helps identify exclusion criteria such as HIV, hepatitis A, B or C, syphilis or another active infectious disease and reduces the risk of unnecessary travel. Certain medical or substance-use risk factors may also prevent treatment.

If the preliminary results do not show an exclusion criterion, the patient can travel to ANOVA IRM in Offenbach. On the first day, ANOVA repeats the required bloodwork as part of its eligibility and processing protocol.

ANOVA also reviews the ED-specific diagnostic findings described above and may complete additional bloodwork or penile imaging where needed. This work-up helps identify the probable cause and severity of ED and informs whether MSEC therapy may be medically appropriate.

Treatment can proceed only after the physician confirms eligibility and determines that the individual assessment supports treatment.

Step 3: Erectile Dysfunction Treatment Planning

ANOVA develops an individualized application schedule after reviewing the patient's diagnostic findings, medical history and previous treatment response. Overall health and travel requirements are also considered.

Standard protocol patterns may provide a starting framework:

  • Intense: Applications occur in closer succession and may be considered for more acute ED cases or when a compressed schedule is medically appropriate.
  • Balanced-Boost: Applications are distributed over a longer period and may be considered for chronic ED or patients with limited travel availability.

These are examples rather than fixed schedules. The physician adjusts the timing and distribution of doses according to the individual treatment plan.

ANOVA reviews the proposed schedule, travel requirements and estimated cost with the patient before treatment proceeds.

Step 4: Treatment Preparation

After evaluation, ANOVA confirms whether treatment will involve MSEC, BMC alone or a combination of both.

Treatment involving MSEC

The initial visit to Offenbach generally requires approximately two consecutive days. Required testing and medical confirmation take place on the first day, with mini-liposuction usually planned for the following day.

A limited amount of abdominal fat is collected under light sedation. Mesenchymal stem cells are isolated from the adipose tissue and cultivated so that the substances they release can be used to produce the patient's MSEC.

The final preparation no longer contains living MSCs. Production and quality control take approximately four weeks, and the patient does not need to remain in Germany during this period.

BMC-only treatment

Bone marrow is collected and processed without mini-liposuction or the four-week MSEC production period. Depending on the individual schedule, BMC collection and application may be completed without a return visit.

When BMC and MSEC are combined, ANOVA coordinates both procedures within the individual treatment plan.

Step 5: MSEC Applications, If Included

If the treatment plan includes MSEC, the patient returns to Offenbach after production is complete. Applications follow the individualized schedule established during treatment planning.

Any stored MSEC doses must be used within the two-year storage period. Further MSEC treatment beyond the available doses or storage period would require another medical review and tissue collection.

Treatment Timeline and Travel Requirements

Initial analysis and counselling can normally begin remotely. The in-person MSEC process is then built around three stages:

  • Eligibility testing and mini-liposuction: Approximately two consecutive days in Offenbach
  • MSEC production: Approximately four weeks, during which the patient can return home
  • MSEC applications: Return visits to Offenbach according to the individual treatment plan, with any stored doses used within two years

Patients receiving BMC alone may not require a return visit. For combined BMC and MSEC treatment, ANOVA confirms the procedural and travel schedule individually.

The number and timing of return visits depend on the treatment plan and the patient's travel distance. International patients receiving MSEC should expect repeated travel if they intend to complete all planned applications.

Cost of Stem Cell Therapy for Erectile Dysfunction

MSEC treatment generally costs approximately €20,000 to €36,000, depending on the total number of doses used.

Costs for BMC alone or combined BMC and MSEC treatment are determined individually.

ANOVA IRM provides an individualized estimate before treatment. International patients should budget separately for travel and accommodation.

Does Health Insurance Cover the Therapy Costs?

Experimental MSEC therapy and BMC treatment included in an individual ED treatment plan are generally not covered by health insurance.

Patients should expect to pay for treatment themselves unless their insurer confirms otherwise. Insurance coverage should not be assumed.

Why Choose ANOVA IRM for Erectile Dysfunction Treatment?

  • Cause-focused medical assessment: ANOVA reviews physical, psychological and mixed contributors before a treatment approach is selected.
  • Specialized ED diagnostics: ANOVA typically recommends SKAT-MRI, a penile MRI performed during a pharmacologically induced erection, to evaluate structural and vascular contributors to ED.
  • Autologous MSEC production: ANOVA produces MSEC from the patient's own adipose-derived mesenchymal stem cells rather than donor-derived material.
  • Cell-free MSEC concept: The final MSEC preparation contains secreted factors rather than living MSCs.
  • Imaging-informed treatment planning: ANOVA uses diagnostic imaging findings to identify probable anatomical contributors and guide individualized treatment planning.
  • Controlled treatment in Germany: Treatment takes place at ANOVA IRM in Offenbach within a regulated medical setting and includes product quality controls.
  • Individual treatment planning: Diagnostic findings, established care, eligibility, travel, cost and experimental status are reviewed before treatment.

Request a Medical Evaluation

Find out whether ANOVA's stem cell-based approach may be medically appropriate for your type of erectile dysfunction.

ANOVA IRM can begin with a remote medical review before you travel to Germany. The patient care team can explain what information is needed, outline the next steps and help arrange a physician consultation.

Treatment is considered after an individual medical review of the ED diagnosis, underlying contributors, previous care and procedural suitability.

Contact ANOVA IRM to begin your confidential remote medical evaluation.

Frequently Asked Questions About Stem Cell Therapy for Erectile Dysfunction

Is Stem Cell Therapy for Erectile Dysfunction Available at ANOVA IRM?

Yes. ANOVA IRM evaluates selected patients for experimental autologous MSEC therapy. Depending on the diagnostic findings and physician assessment, BMC may be used as a standalone treatment or combined with MSEC.

The process begins with a medical review to identify the probable cause of ED and determine whether further assessment may be appropriate.

Does Stem Cell Therapy Work for Erectile Dysfunction?

Stem cell-based treatment for ED remains under investigation. Laboratory and animal studies have reported effects on vascular, nerve and erectile-tissue pathways, while small early human studies of several living-cell products have reported encouraging findings in some patient groups.

Because these studies used different cell products, treatment methods and patient populations, the results remain preliminary. They provide scientific background for regenerative approaches to ED but are not direct evidence for ANOVA's cell-free MSEC therapy.

Who May Be a Candidate for ED Stem Cell Therapy?

ANOVA may consider selected patients with persistent ED and a suspected or confirmed physical component, including vascular, neurological, metabolic, postsurgical or trauma-related factors. Suitability also depends on overall health, previous treatment, diagnostic findings and procedural safety.

Can MSEC Therapy Help ED After Prostate Cancer Treatment?

ED following prostate surgery or radiation may involve nerve, vascular and erectile-tissue changes that are relevant to regenerative research.

ANOVA must review the patient's diagnosis, previous cancer treatment, current cancer status and the clinic's cancer-related eligibility requirements before treatment can be considered.

What Is MSEC / Stem Cell Secretome Therapy?

MSEC stands for Mesenchymal Stem Cell Secretome. It is a cell-free, exosome-containing preparation composed of substances released by mesenchymal stem cells.

At ANOVA IRM, MSEC is produced using the patient's own adipose-derived mesenchymal stem cells. The final preparation contains the substances released by those cells rather than living MSCs.

Does MSEC Replace Viagra, Cialis or Other ED Treatments?

No. PDE5 inhibitors, management of contributing health conditions, psychological care, vacuum devices, injectable medication or a penile prosthesis may remain appropriate.

MSEC may be considered alongside established care within an individualized treatment plan. Patients should not stop prescribed ED treatment without consulting their physician.

Can International Patients Apply for Treatment?

Yes. The initial medical review and physician consultation can usually begin remotely. Travel to Offenbach, Germany, is required for final assessment and treatment. Patients receiving MSEC return for subsequent applications according to the individual plan.

References

  1. European Association of Urology. EAU Guidelines on Sexual and Reproductive Health: Management of Erectile Dysfunction. Accessed July 31, 2026.
  2. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54–61.
  3. Litwin MS, Nied RJ, Dhanani N. Health-related quality of life in men with erectile dysfunction. J Gen Intern Med. 1998;13:159–166.
  4. Lue TF, Lee KL. Pharmacotherapy for erectile dysfunction. Chin Med J (Engl). 2000;113:291–298.
  5. Dorsey P, Keel C, Klavens M, Hellstrom WJG. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction. Expert Opin Pharmacother. 2010;11:1109–1122.
  6. Alwaal A, Hussein AA, Lin CS, Lue TF. Prospects of stem cell treatment in benign urological diseases. Korean J Urol. 2015;56:257–265.
  7. Soebadi MA, Moris L, Castiglione F, Weyne E, Albersen M. Advances in stem cell research for the treatment of male sexual dysfunctions. Curr Opin Urol. 2016;26:129–139.
  8. Lue TF. Erectile dysfunction. N Engl J Med. 2000;342:1802–1813.
  9. Prieto D. Physiological regulation of penile arteries and veins. Int J Impot Res. 2008;20:17–29.
  10. Lin CS, Xin ZC, Wang Z, et al. Stem cell therapy for erectile dysfunction: a critical review. Stem Cells Dev. 2012;21:343–351.
  11. Mulhall JP, Bella AJ, Briganti A, et al. Erectile function rehabilitation in the radical prostatectomy patient. J Sex Med. 2010;7:1687–1698.
  12. Iacono F, Giannella R, Somma P, Manno G, Fusco F, Mirone V. Histological alterations in cavernous tissue after radical prostatectomy. J Urol. 2005;173:1673–1676.
  13. Fode M, Ohl DA, Ralph D, Sønksen J. Penile rehabilitation after radical prostatectomy: what the evidence really says. BJU Int. 2013;112:998–1008.
  14. Dashwood MR, Crump A, Shi-Wen X, et al. Identification of neuronal nitric oxide synthase in the human penis: a potential role of reduced neuronally derived nitric oxide in erectile dysfunction. Curr Pharm Biotechnol. 2011;12:1316–1321.
  15. Gratzke C, Angulo J, Chitaley K, et al. Anatomy, physiology and pathophysiology of erectile dysfunction. J Sex Med. 2010;7:445–475.
  16. Huang YC, Ning H, Shindel AW, et al. The effect of intracavernous injection of adipose tissue-derived stem cells on hyperlipidemia-associated erectile dysfunction in a rat model. J Sex Med. 2010;7:1391–1400.
  17. Zhang H, Yang R, Wang Z, et al. Adipose tissue-derived stem cells secrete CXCL5 cytokine with neurotrophic effects on cavernous nerve regeneration. J Sex Med. 2011;8:437–446.
  18. Albersen M, Lin CS, Lue TF. Stem-cell therapy for erectile dysfunction. Arab J Urol. 2013;11:237–244.
  19. Qiu X, Villalta J, Ferretti L, et al. Effects of intravenous injection of adipose-derived stem cells in a rat model of radiation therapy-induced erectile dysfunction. J Sex Med. 2012;9:1834–1841.
  20. You D, Jang MJ, Lee J, et al. Periprostatic implantation of human bone marrow-derived mesenchymal stem cells potentiates recovery of erectile function by intracavernosal injection in a rat model of cavernous nerve injury. Urology. 2013;81:104–110.
  21. You D, Jang MJ, Lee J, et al. Comparative analysis of periprostatic implantation and intracavernosal injection of human adipose tissue-derived stem cells for erectile-function recovery in a rat model of cavernous nerve injury. Prostate. 2013;73:278–286.
  22. Lin CS, Xin Z, Dai J, Huang YC, Lue TF. Stem-cell therapy for erectile dysfunction. Expert Opin Biol Ther. 2013;13:1585–1597.
  23. Bahk JY, Jung JH, Han H, et al. Treatment of diabetic impotence with umbilical cord blood stem-cell intracavernosal transplant: preliminary report of seven cases. Exp Clin Transplant. 2010;8:150–160.
  24. Yiou R, Hamidou L, Birebent B, et al. Safety of intracavernous bone marrow-mononuclear cells for postradical prostatectomy erectile dysfunction: an open dose-escalation pilot study. Eur Urol. 2016;69:988–991.
  25. Haahr MK, Jensen CH, Toyserkani NM, et al. Safety and potential effect of a single intracavernous injection of autologous adipose-derived regenerative cells in patients with erectile dysfunction following radical prostatectomy: an open-label phase I clinical trial. EBioMedicine. 2016;5:204–210.
  26. Levy JA, Marchand M, Iorio L, et al. Determining the feasibility of managing erectile dysfunction in humans with placental-derived stem cells. J Am Osteopath Assoc. 2016;116:e1–e5.
  27. Fandel TM, Albersen M, Lin G, et al. Recruitment of intracavernously injected adipose-derived stem cells to the major pelvic ganglion improves erectile function in a rat model of cavernous nerve injury. Eur Urol. 2012;61:201–210.
  28. Takayanagi A, Sasaki M, Kataoka-Sasaki Y, et al. Intravenous preload of mesenchymal stem cells rescues erectile function in a rat model of cavernous nerve injury. J Sex Med. 2015;12:1713–1721.
  29. Vakalopoulos I, Memmos D, Mykoniatis I, Toutziaris C, Dimitriadis G. Stem cell therapy in erectile dysfunction: science fiction or realistic treatment option? Hormones. 2018;17:315–320.
  30. Wu H, Tang WH, Zhao LM, et al. Nanotechnology-assisted adipose-derived stem cell therapy for erectile dysfunction following cavernous nerve injury: in vivo cell tracking, optimized injection dosage and functional evaluation. Asian J Androl. 2018;20:442–447.
  31. Matz EL, Terlecki R, Zhang Y, Jackson J, Atala A. Stem cell therapy for erectile dysfunction. Sex Med Rev. 2019;7:321–328.
  32. Shan H, Chen F, Zhang T, He S, Xu L, Wei A. Stem cell therapy for erectile dysfunction in rats with cavernous nerve injury: a systematic review and meta-analysis. PLoS ONE. 2015;10:e0121428.
  33. You D, Jang MJ, Lee J, et al. Comparative study of autologous stromal vascular fraction and adipose-derived stem cells for erectile-function recovery in a rat model of cavernous nerve injury. Stem Cells Transl Med. 2015;4:351–358.
  34. Chen X, Yang Q, Zheng T, et al. Neurotrophic effect of adipose tissue-derived stem cells on erectile-function recovery through pigment epithelium-derived factor secretion in a rat model of cavernous nerve injury. Stem Cells Int. 2016;2016:5161248.
  35. Wang XY, Liu CL, Li SD, et al. Hypoxia preconditioning promotes adipose-derived mesenchymal stem cell-based repair of diabetic erectile dysfunction by augmenting angiogenesis and neuroprotection. PLoS ONE. 2015;10:e0118951.
  36. Bochinski D, Lin GT, Nunes L, et al. The effect of neural embryonic stem-cell therapy in a rat model of cavernous nerve injury. BJU Int. 2004;94:904–909.
  37. Kim Y, de Miguel F, Usiene I, et al. Injection of skeletal muscle-derived cells into the penis improves erectile function. Int J Impot Res. 2006;18:329–334.
  38. Fall PA, Izikki M, Tu L, et al. Apoptosis and effects of intracavernous bone marrow-cell injection in a rat model of postprostatectomy erectile dysfunction. Eur Urol. 2009;56:716–725.
  39. Albersen M, Fandel TM, Lin G, et al. Injections of adipose tissue-derived stem cells and stem-cell lysate improve recovery of erectile function in a rat model of cavernous nerve injury. J Sex Med. 2010;7:3331–3340.
  40. Kendirci M, Trost L, Bakondi B, Whitney MJ, Hellstrom WJG, Spees JL. Transplantation of nonhematopoietic adult bone marrow stem/progenitor cells isolated by p75 nerve growth factor receptor into the penis rescues erectile function in a rat model of cavernous nerve injury. J Urol. 2010;184:1560–1566.
  41. Lin G, Qiu X, Fandel T, et al. Tracking intracavernously injected adipose-derived stem cells to bone marrow. Int J Impot Res. 2011;23:268–275.
  42. Lin G, Albersen M, Harraz AM, et al. Cavernous nerve repair with allogenic adipose matrix and autologous adipose-derived stem cells. Urology. 2011;77:1509.e1–1509.e8.
  43. Woo JC, Bae WJ, Kim SJ, et al. Transplantation of muscle-derived stem cells into the corpus cavernosum restores erectile function in a rat model of cavernous nerve injury. Korean J Urol. 2011;52:359–363.
  44. Kim SJ, Park SH, Sung YC, Kim SW. Effect of mesenchymal stem cells associated with Matrixen on erectile function in a rat model of bilateral cavernous nerve crush injury. Int Braz J Urol. 2012;38:833–841.
  45. Kim SJ, Choi SW, Hur KJ, et al. Synergistic effect of mesenchymal stem cells infected with recombinant adenovirus expressing human BDNF on erectile function in a rat model of cavernous nerve injury. Korean J Urol. 2012;53:726–732.
  46. Kovanecz I, Rivera S, Nolazco G, et al. Separate or combined treatments with daily sildenafil, molsidomine or muscle-derived stem cells prevent erectile dysfunction in a rat model of cavernosal nerve damage. J Sex Med. 2012;9:2814–2826.
  47. Piao S, Kim IG, Lee JY, et al. Therapeutic effect of adipose-derived stem cells and BDNF-immobilized PLGA membrane in a rat model of cavernous nerve injury. J Sex Med. 2012;9:1968–1979.
  48. Tewari A, Srivastava A, Sooriakumaran P, Grover S, Dorsey P, Leung R. Technique of traction-free nerve-sparing robotic prostatectomy: delicate tissue handling through real-time penile oxygen monitoring. Int J Impot Res. 2012;24:11–19.

  1. Georg Hansmann, Philippe Chouvarine, Franziska Diekmann, Martin Giera, Markus Ralser, Michael Mülleder, Constantin von Kaisenberg, Harald Bertram, Ekaterina Legchenko & Ralf Hass "Human umbilical cord mesenchymal stem cell-derived treatment of severe pulmonary arterial hypertension". Nature Cardiovascular Research volume 1, pages568–576 (2022).
  2. Murphy JM, Fink DJ, Hunziker EB, et al. Stem cell therapy in a caprine model of osteoarthritis . Arthritis Rheum. 2003;48:3464–74.
  3. Lee KB, Hui JH, Song IC, Ardany L, et al. Injectable mesenchymal stem cell therapy for large cartilage defects—a porcine model. Stem Cell. 2007;25:2964–71.
  4. Saw KY, Hussin P, Loke SC, et al. Articular cartilage regeneration with autologous marrow aspirate and hyaluronic acid: an experimental study in a goat model. Arthroscopy . 2009;25(12):1391–400.
  5. Black L, Gaynor J, Adams C, et al. Effect of intra-articular injection of autologous adipose-derived mesenchymal stem and regenerative cells on clinical signs of chronic osteoarthritis of the elbow joint in dogs. Vet Ther. 2008;9:192-200.
  6. Centeno C, Busse D, Kisiday J, et al. Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal stem cells. Pain Physician. 2008;11(3):343–53.
  7. Centeno C, Kisiday J, Freeman M, et al. Partial regeneration of the human hip via autologous bone marrow nucleated cell transfer: a case study. Pain Physician. 2006;9:253–6.
  8. Centeno C, Schultz J, Cheever M. Safety and complications reporting on the re-implantation of culture-expanded mesenchymal stem cells using autologous platelet lysate technique. Curr Stem Cell. 2011;5(1):81–93.
  9. Pak J. Regeneration of human bones in hip osteonecrosis and human cartilage in knee osteoarthritis with autologous adipose derived stem cells: a case series. J Med Case Rep. 2001;5:296.
  10. Kuroda R, Ishida K, et al. Treatment of a full-thickness articular cartilage defect in the femoral condyle of an athlete with autologous bone-marrow stromal cells. Osteoarthritis Cartilage. 2007;15:226–31.
  11. Emadedin M, Aghdami N, Taghiyar L, et al. Intra-articular injection of autologous mesenchymal stem cells in six patients with knee osteoarthritis. Arch Iran Med. 2012;15(7):422–8.
  12. Saw KY et al. Articular cartilage regeneration with autologous peripheral blood stem cells versus hyaluronic acid: a randomized controlled trial. Arthroscopy. 2013;29(4):684–94.
  13. Vangsness CT, Farr J, Boyd J, et al. Adult human mesenchymal stem cells delivered via intra-articular injection to the knee following partial medial meniscectomy. J Bone Joint Surg. 2014;96(2):90–8.
  14. Freitag, Julien, et al. Mesenchymal stem cell therapy in the treatment of osteoarthritis: reparative pathways, safety and efficacy–a review. BMC musculoskeletal disorders 17.1 (2016): 230.
  15. Maumus, Marie, Christian Jorgensen, and Danièle Noël. " Mesenchymal stem cells in regenerative medicine applied to rheumatic diseases: role of secretome and exosomes. " Biochimie 95.12 (2013): 2229-2234.
  16. Dostert, Gabriel, et al. " How do mesenchymal stem cells influence or are influenced by microenvironment through extracellular vesicles communication?. " Frontiers in Cell and Developmental Biology 5 (2017).
  17. Chaparro, Orlando, and Itali Linero. " Regenerative Medicine: A New Paradigm in Bone Regeneration. " (2016).
  18. Toh, Wei Seong, et al. " MSC exosome as a cell-free MSC therapy for cartilage regeneration: Implications for osteoarthritis treatment. " Seminars in Cell & Developmental Biology. Academic Press, 2016.
  19. Chaparro, Orlando, and Itali Linero. " Regenerative Medicine: A New Paradigm in Bone Regeneration. " (2016).
  20. S. Koelling, J. Kruegel, M. Irmer, J.R. Path, B. Sadowski, X. Miro, et al., Migratory chondrogenic progenitor cells from repair tissue during the later stages of human osteoarthritis , Cell Stem Cell 4 (2009) 324–335.
  21. B.A. Jones, M. Pei, Synovium-Derived stem cells: a tissue-Specific stem cell for cartilage engineering and regeneration , Tissue Eng. B: Rev. 18 (2012) 301–311.
  22. W. Ando, J.J. Kutcher, R. Krawetz, A. Sen, N. Nakamura, C.B. Frank, et al., Clonal analysis of synovial fluid stem cells to characterize and identify stable mesenchymal stromal cell/mesenchymal progenitor cell phenotypes in a porcine model: a cell source with enhanced commitment to the chondrogenic lineage, Cytotherapy 16 (2014) 776–788.
  23. K.B.L. Lee, J.H.P. Hui, I.C. Song, L. Ardany, E.H. Lee, Injectable mesenchymal stem cell therapy for large cartilage defects—a porcine model, Stem Cells 25 (2007) 2964–2971.
  24. W.-L. Fu, C.-Y. Zhou, J.-K. Yu, A new source of mesenchymal stem cells for articular cartilage repair: mSCs derived from mobilized peripheral blood share similar biological characteristics in vitro and chondrogenesis in vivo as MSCs from bone marrow in a rabbit model , Am. J. Sports Med. 42 (2014) 592–601.
  25. X. Xie, Y. Wang, C. Zhao, S. Guo, S. Liu, W. Jia, et al., Comparative evaluation of MSCs from bone marrow and adipose tissue seeded in PRP-derived scaffold for cartilage regeneration , Biomaterials 33 (2012) 7008–7018.
  26. E.-R. Chiang, H.-L. Ma, J.-P. Wang, C.-L. Liu, T.-H. Chen, S.-C. Hung, Allogeneic mesenchymal stem cells in combination with hyaluronic acid for the treatment of osteoarthritis in rabbits , PLoS One 11 (2016) e0149835.
  27. H. Nejadnik, J.H. Hui, E.P. Feng Choong, B.-C. Tai, E.H. Lee, Autologous bone marrow–derived mesenchymal stem cells versus autologous chondrocyte implantation: an observational cohort study , Am. J. Sports Med. 38 (2010) 1110–1116.
  28. I. Sekiya, T. Muneta, M. Horie, H. Koga, Arthroscopic transplantation of synovial stem cells improves clinical outcomes in knees with cartilage defects , Clin. Orthop. Rel. Res. 473 (2015) 2316–2326.
  29. Y.S. Kim, Y.J. Choi, Y.G. Koh, Mesenchymal stem cell implantation in knee osteoarthritis: an assessment of the factors influencing clinical outcomes , Am. J. Sports Med. 43 (2015) 2293–2301.
  30. W.-L. Fu, Y.-F. Ao, X.-Y. Ke, Z.-Z. Zheng, X. Gong, D. Jiang, et al., Repair of large full-thickness cartilage defect by activating endogenous peripheral blood stem cells and autologous periosteum flap transplantation combined with patellofemoral realignment , Knee 21 (2014) 609–612.
  31. Y.-G. Koh, O.-R. Kwon, Y.-S. Kim, Y.-J. Choi, D.-H. Tak, Adipose-derived mesenchymal stem cells with microfracture versus microfracture alone: 2-year follow-up of a prospective randomized trial , Arthrosc. J. Arthrosc. Relat. Surg. 32 (2016) 97–109.
  32. T.S. de Windt, L.A. Vonk, I.C.M. Slaper-Cortenbach, M.P.H. van den Broek, R. Nizak, M.H.P. van Rijen, et al., Allogeneic mesenchymal stem cells stimulate cartilage regeneration and are safe for single-Stage cartilage repair in humans upon mixture with recycled autologous chondrons , Stem Cells (2016) (n/a-n/a).
  33. L. da Silva Meirelles, A.M. Fontes, D.T. Covas, A.I. Caplan, Mechanisms involved in the therapeutic properties of mesenchymal stem cells , Cytokine Growth Factor Rev. 20 (2009) 419–427.
  34. W.S. Toh, C.B. Foldager, M. Pei, J.H.P. Hui, Advances in mesenchymal stem cell-based strategies for cartilage repair and regeneration , Stem Cell Rev. Rep. 10 (2014) 686–696.
  35. R.C. Lai, F. Arslan, M.M. Lee, N.S.K. Sze, A. Choo, T.S. Chen, et al., Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury , Stem Cell Res. 4 (2010) 214–222.
  36. S. Zhang, W.C. Chu, R.C. Lai, S.K. Lim, J.H.P. Hui, W.S. Toh, Exosomes derived from human embryonic mesenchymal stem cells promote osteochondral regeneration, Osteoarthr . Cartil. 24 (2016) 2135–2140.
  37. S. Zhang, W. Chu, R. Lai, J. Hui, E. Lee, S. Lim, et al., 21 – human mesenchymal stem cell-derived exosomes promote orderly cartilage regeneration in an immunocompetent rat osteochondral defect model , Cytotherapy 18 (2016) S13.
  38. C.T. Lim, X. Ren, M.H. Afizah, S. Tarigan-Panjaitan, Z. Yang, Y. Wu, et al., Repair of osteochondral defects with rehydrated freeze-dried oligo[poly(ethylene glycol) fumarate] hydrogels seeded with bone marrow mesenchymal stem cells in a porcine model
  39. A. Gobbi, G. Karnatzikos, S.R. Sankineani, One-step surgery with multipotent stem cells for the treatment of large full-thickness chondral defects of the knee , Am. J. Sports Med. 42 (2014) 648–657.
  40. A. Gobbi, C. Scotti, G. Karnatzikos, A. Mudhigere, M. Castro, G.M. Peretti, One-step surgery with multipotent stem cells and Hyaluronan-based scaffold for the treatment of full-thickness chondral defects of the knee in patients older than 45 years , Knee Surg. Sports Traumatol. Arthrosc. (2016) 1–8.
  41. A. Gobbi, G. Karnatzikos, C. Scotti, V. Mahajan, L. Mazzucco, B. Grigolo, One-step cartilage repair with bone marrow aspirate concentrated cells and collagen matrix in full-thickness knee cartilage lesions: results at 2-Year follow-up , Cartilage 2 (2011) 286–299.
  42. K.L. Wong, K.B.L. Lee, B.C. Tai, P. Law, E.H. Lee, J.H.P. Hui, Injectable cultured bone marrow-derived mesenchymal stem cells in varus knees with cartilage defects undergoing high tibial osteotomy: a prospective, randomized controlled clinical trial with 2 years’ follow-up , Arthrosc. J. Arthrosc. Relat. Surg. 29 (2013) 2020–2028.
  43. J.M. Hare, J.E. Fishman, G. Gerstenblith, et al., Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the poseidon randomized trial, JAMA 308 (2012) 2369–2379.
  44. L. Wu, J.C.H. Leijten, N. Georgi, J.N. Post, C.A. van Blitterswijk, M. Karperien, Trophic effects of mesenchymal stem cells increase chondrocyte proliferation and matrix formation , Tissue Eng. A 17 (2011) 1425–1436.
  45. L. Wu, H.-J. Prins, M.N. Helder, C.A. van Blitterswijk, M. Karperien, Trophic effects of mesenchymal stem cells in chondrocyte Co-Cultures are independent of culture conditions and cell sources , Tissue Eng. A 18 (2012) 1542–1551.
  46. S.K. Sze, D.P.V. de Kleijn, R.C. Lai, E. Khia Way Tan, H. Zhao, K.S. Yeo, et al., Elucidating the secretion proteome of human embryonic stem cell-derived mesenchymal stem cells , Mol. Cell. Proteomics 6 (2007) 1680–1689.
  47. M.B. Murphy, K. Moncivais, A.I. Caplan, Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine , Exp. Mol. Med. 45 (2013) e54.
  48. M.J. Lee, J. Kim, M.Y. Kim, Y.-S. Bae, S.H. Ryu, T.G. Lee, et al., Proteomic analysis of tumor necrosis factor--induced secretome of human adipose tissue-derived mesenchymal stem cells , J. Proteome Res. 9 (2010) 1754–1762.
  49. S. Bruno, C. Grange, M.C. Deregibus, R.A. Calogero, S. Saviozzi, F. Collino, et al., Mesenchymal stem cell-derived microvesicles protect against acute tubular injury, J. Am. Soc. Nephrol. 20 (2009) 1053–1067.
  50. M. Yá˜nez-Mó, P.R.-M. Siljander, Z. Andreu, A.B. Zavec, F.E. Borràs, E.I. Buzas, et al. Biological properties of extracellular vesicles and their physiological functions (2015).
  51. C. Lawson, J.M. Vicencio, D.M. Yellon, S.M. Davidson, Microvesicles and exosomes: new players in metabolic and cardiovascular disease , J. Endocrinol. 228 (2016) R57–R71.
  52. A.G. Thompson, E. Gray, S.M. Heman-Ackah, I. Mager, K. Talbot, S.E. Andaloussi, et al., Extracellular vesicles in neurodegenerative diseas—pathogenesis to biomarkers, Nat. Rev. Neurol. 12 (2016) 346–357.
  53. I.E.M. Bank, L. Timmers, C.M. Gijsberts, Y.-N. Zhang, A. Mosterd, J.-W. Wang, et al., The diagnostic and prognostic potential of plasma extracellular vesicles for cardiovascular disease , Expert Rev. Mol. Diagn. 15 (2015) 1577–1588.
  54. T. Kato, S. Miyaki, H. Ishitobi, Y. Nakamura, T. Nakasa, M.K. Lotz, et al., Exosomes from IL-1 stimulated synovial fibroblasts induce osteoarthritic changes in articular chondrocytes , Arthritis. Res. Ther. 16 (2014) 1–11.
  55. R.W.Y. Yeo, S.K. Lim, Exosomes and their therapeutic applications, in: C. Gunther, A. Hauser, R. Huss (Eds.), Advances in Pharmaceutical Cell TherapyPrinciples of Cell-Based Biopharmaceuticals, World Scientific, Singapore, 2015, pp. 477–491.
  56. X. Qi, J. Zhang, H. Yuan, Z. Xu, Q. Li, X. Niu, et al., Exosomes secreted by human-Induced pluripotent stem cell-derived mesenchymal stem cells repair critical-sized bone defects through enhanced angiogenesis and osteogenesis in osteoporotic rats , Int. J. Biol. Sci. 12 (2016) 836–849.
  57. R.C. Lai, F. Arslan, S.S. Tan, B. Tan, A. Choo, M.M. Lee, et al., Derivation and characterization of human fetal MSCs: an alternative cell source for large-scale production of cardioprotective microparticles , J. Mol. Cell. Cardiol. 48 (2010) 1215–1224.
  58. Y. Zhou, H. Xu, W. Xu, B. Wang, H. Wu, Y. Tao, et al., Exosomes released by human umbilical cord mesenchymal stem cells protect against cisplatin-induced renal oxidative stress and apoptosis in vivo and in vitro , Stem Cell Res. Ther. 4 (2013) 1–13.
  59. Y. Qin, L. Wang, Z. Gao, G. Chen, C. Zhang, Bone marrow stromal/stem cell-derived extracellular vesicles regulate osteoblast activity and differentiation in vitro and promote bone regeneration in vivo , Sci. Rep. 6 (2016) 21961.
  60. M. Nakano, K. Nagaishi, N. Konari, Y. Saito, T. Chikenji, Y. Mizue, et al., Bone marrow-derived mesenchymal stem cells improve diabetes-induced cognitive impairment by exosome transfer into damaged neurons and astrocytes , Sci. Rep. 6 (2016) 24805.
  61. K. Nagaishi, Y. Mizue, T. Chikenji, M. Otani, M. Nakano, N. Konari, et al., Mesenchymal stem cell therapy ameliorates diabetic nephropathy via the paracrine effect of renal trophic factors including exosomes , Sci. Rep. 6 (2016) 34842.
  62. S.R. Baglio, K. Rooijers, D. Koppers-Lalic, F.J. Verweij, M. Pérez Lanzón, N. Zini, et al., Human bone marrow- and adipose-mesenchymal stem cells secrete exosomes enriched in distinctive miRNA and tRNA species , Stem Cell Res. Ther. 6 (2015) 1–20.
  63. T. Chen, R. Yeo, F. Arslan, Y. Yin, S. Tan, Efficiency of exosome production correlates inversely with the developmental maturity of MSC donor, J. Stem Cell Res. Ther. 3 (2013) 2.
  64. R.C. Lai, S.S. Tan, B.J. Teh, S.K. Sze, F. Arslan, D.P. de Kleijn, et al., Proteolytic potential of the MSC exosome proteome: implications for an exosome-mediated delivery of therapeutic proteasome , Int. J. Proteomics 2012 (2012) 971907.
  65. T.S. Chen, R.C. Lai, M.M. Lee, A.B.H. Choo, C.N. Lee, S.K. Lim, Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs , Nucleic Acids Res. 38 (2010) 215–224.
  66. R.W. Yeo, R.C. Lai, K.H. Tan, S.K. Lim, Exosome: a novel and safer therapeutic refinement of mesenchymal stem cell, J. Circ. Biomark. 1 (2013) 7.
  67. R.C. Lai, R.W. Yeo, S.K. Lim, Mesenchymal stem cell exosomes, Semin. Cell Dev. Biol. 40 (2015) 82–88.
  68. B. Zhang, R.W. Yeo, K.H. Tan, S.K. Lim, Focus on extracellular vesicles: therapeutic potential of stem cell-derived extracellular vesicles , Int. J. Mol. Sci. 17 (2016) 174.
  69. Hu G-w, Q. Li, X. Niu, B. Hu, J. Liu, Zhou S-m, et al., Exosomes secreted by human-induced pluripotent stem cell-derived mesenchymal stem cells attenuate limb ischemia by promoting angiogenesis in mice , Stem Cell Res. Ther. 6 (2015) 1–15.
  70. J. Zhang, J. Guan, X. Niu, G. Hu, S. Guo, Q. Li, et al., Exosomes released from human induced pluripotent stem cells-derived MSCs facilitate cutaneous wound healing by promoting collagen synthesis and angiogenesis , J. Transl. Med. 13 (2015) 1–14.
  71. B. Zhang, M. Wang, A. Gong, X. Zhang, X. Wu, Y. Zhu, et al., HucMSC-exosome mediated-Wnt4 signaling is required for cutaneous wound healing, Stem Cells 33 (2015) 2158–2168.
  72. B. Zhang, Y. Yin, R.C. Lai, S.S. Tan, A.B.H. Choo, S.K. Lim, Mesenchymal stem cells secrete immunologically active exosomes , Stem Cells Dev. 23 (2013) 1233–1244.
  73. C.Y. Tan, R.C. Lai, W. Wong, Y.Y. Dan, S.-K. Lim, H.K. Ho, Mesenchymal stem cell-derived exosomes promote hepatic regeneration in drug-induced liver injury models , Stem Cell Res. Ther. 5 (2014) 1–14.
  74. C. Lee, S.A. Mitsialis, M. Aslam, S.H. Vitali, E. Vergadi, G. Konstantinou, et al., Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension , Circulation 126 (2012) 2601–2611.
  75. B. Yu, H. Shao, C. Su, Y. Jiang, X. Chen, L. Bai, et al., Exosomes derived from MSCs ameliorate retinal laser injury partially by inhibition of MCP-1 , Sci. Rep. 6 (2016) 34562.
  76. Jo CH, Lee YG, Shin WH, et al. Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof of concept clinical trial. Stem Cells. 2014;32(5):1254–66.
  77. Vega, Aurelio, et al. Treatment of knee osteoarthritis with allogeneic bone marrow mesenchymal stem cells: a randomized controlled trial. Transplantation. 2015;99(8):1681–90.
  78. Davatchi F, Sadeghi-Abdollahi B, Mohyeddin M, et al. Mesenchymal stem cell therapy for knee osteoarthritis. Preliminary report of four patients. Int J Rheum Dis. 2011;14(2):211–5
  79. Hernigou P, Flouzat Lachaniette CH, Delambre J, et al. Biologic augmentation of rotator cuff repair with mesenchymal stem cells during arthroscopy improves healing and prevents further tears: a case- controlled study. Int Orthop. 2014;38(9):1811–1818
  80. Galli D, Vitale M, Vaccarezza M. Bone marrow-derived mesenchymal cell differentiation toward myogenic lineages: facts and perspectives. Biomed Res Int. 2014;2014:6.
  81. Beitzel K, Solovyova O, Cote MP, et al. The future role of mesenchymal Stem cells in The management of shoulder disorders . Arthroscopy. 2013;29(10):1702–1711.
  82. Isaac C, Gharaibeh B, Witt M, Wright VJ, Huard J. Biologic approaches to enhance rotator cuff healing after injury. J Shoulder Elbow Surg. 2012;21(2):181–190.
  83. Malda, Jos, et al. " Extracellular vesicles [mdash] new tool for joint repair and regeneration. " Nature Reviews Rheumatology (2016).

  1. Xu, Ming, et al. " Transplanted senescent cells induce an osteoarthritis-like condition in mice. " The Journals of Gerontology Series A: Biological Sciences and Medical Sciences (2016): glw154.
  2. McCulloch, Kendal, Gary J. Litherland, and Taranjit Singh Rai. " Cellular senescence in osteoarthritis pathology ." Aging Cell (2017).

Contraindications

Our stem cell treatments are experimental, but we only treat patients for whom we believe the risk/benefit ratio indicates treatment based on the state of the art, i.e., medical, scientific evidence.

Please understand that we therefore do not treat patients for whom the following points apply:

  • Active cancer in the last two years
  • Not yet of legal age
  • Existing pregnancy or lactation period
  • Unable to breathe on own, ventilator
  • Difficulty breathing in supine position
  • Dysphagia (extreme difficulty swallowing)
  • Psychiatric disorder
  • Active infectious disease (Hepatitis A, B, C, HIV, Syphilis, or other)